OXNAD1 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-09874
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit
Concentration
0.5 mg/ml
Product Specifications
Immunogen
The immunogen is a synthetic peptide directed towards the C-terminal region of Human OXNAD1 (NP_612390). Peptide sequence ILRHAADLLREQANKRNGYEIGTIKLFYSAKNTSELLFKKNILDLVNEFP
Clonality
Polyclonal
Host
Rabbit
Theoretical MW
33 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for OXNAD1 Antibody
Western Blot: OXNAD1 Antibody [NBP3-09874]
Western Blot: OXNAD1 Antibody [NBP3-09874] - Western blot analysis of OXNAD1 in Hela Whole Cell lysates. Antibody dilution at 1.0ug/mlApplications for OXNAD1 Antibody
Application
Recommended Usage
Western Blot
1.0 ug/ml
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: OXNAD1
Alternate Names
MGC15763, oxidoreductase NAD-binding domain containing 1, oxidoreductase NAD-binding domain-containing protein 1
Gene Symbol
OXNAD1
Additional OXNAD1 Products
Product Specific Notices for OXNAD1 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...